Emelie Gozzi - C Rad Global Director
| CRAD-B Stock | SEK 30.50 0.10 0.33% |
Insider
Emelie Gozzi is Global Director of C Rad AB
| Phone | 46 18 66 69 30 |
| Web | https://www.c-rad.se |
C Rad Management Efficiency
The company has return on total asset (ROA) of 0.0422 % which means that it generated a profit of $0.0422 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0317 %, meaning that it generated $0.0317 on every $100 dollars invested by stockholders. C Rad's management efficiency ratios could be used to measure how well C Rad manages its routine affairs as well as how well it operates its assets and liabilities.C Rad AB has accumulated 4.1 M in total debt with debt to equity ratio (D/E) of 3.2, implying the company greatly relies on financing operations through barrowing. C Rad AB has a current ratio of 2.44, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist C Rad until it has trouble settling it off, either with new capital or with free cash flow. So, C Rad's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like C Rad AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CRAD-B to invest in growth at high rates of return. When we think about C Rad's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Petra Jansson | RaySearch Laboratories AB | 50 | |
| Lars LLB | Biotage AB | 62 | |
| CS BSc | Biotage AB | 50 | |
| Johan Lof | RaySearch Laboratories AB | 54 | |
| Emil Billbck | Bonesupport Holding AB | 53 | |
| Yve Thorenburg | CellaVision AB | 65 | |
| Nina Wallander | CellaVision AB | 49 | |
| Christina Hugosson | Boule Diagnostics AB | 60 | |
| Julien Veyssy | CellaVision AB | 40 | |
| JonSverre Schanche | Biotage AB | 66 | |
| Maths hc | CellaVision AB | 57 | |
| Michael Roth | Bonesupport Holding AB | 60 | |
| Annette Colin | Boule Diagnostics AB | N/A | |
| Mikael Ekholm | Boule Diagnostics AB | 61 | |
| Mattias Isaksson | Boule Diagnostics AB | N/A | |
| Fredrik Lofman | RaySearch Laboratories AB | 45 | |
| Simon Ostergaard | CellaVision AB | 52 | |
| Petra Duprez | Biotage AB | 58 | |
| AnnMarie Thor | Bonesupport Holding AB | N/A | |
| Scott Carr | Biotage AB | 56 | |
| Michael MD | Bonesupport Holding AB | 49 | |
Management Performance
| Return On Equity | 0.0317 | |||
| Return On Asset | 0.0422 |
C Rad AB Leadership Team
Elected by the shareholders, the C Rad's board of directors comprises two types of representatives: C Rad inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CRAD-B. The board's role is to monitor C Rad's management team and ensure that shareholders' interests are well served. C Rad's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, C Rad's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xiaodong Wang, Pres China | ||
| Tim Thurn, CEO Pres | ||
| Ivan Astralaga, Pres Americas | ||
| Hakan Axelsson, Chief Officer | ||
| Emelie Gozzi, Global Director | ||
| Priscilla Kazumba, Digital Coordinator | ||
| Lars Levin, Interim Officer |
CRAD-B Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is C Rad a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0317 | |||
| Return On Asset | 0.0422 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 1.23 B | |||
| Shares Outstanding | 33.8 M | |||
| Shares Owned By Insiders | 52.18 % | |||
| Shares Owned By Institutions | 18.00 % | |||
| Price To Earning | 46.24 X | |||
| Price To Book | 5.61 X |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in CRAD-B Stock
C Rad financial ratios help investors to determine whether CRAD-B Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CRAD-B with respect to the benefits of owning C Rad security.